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Background: Vaccination of young calves against Bovine viral diarrhea virus (BVDV) is desirable in dairy and beef
operations to reduce clinical disease and prevent spread of the virus among cattle. Although protection from clinical
disease by multivalent, modified-live virus (MLV) vaccines has been demonstrated, the ability of MLV vaccines to
prevent viremia and viral shedding in young calves possessing passive immunity is not known. The purpose of
this study was to compare the ability of three different MLV vaccines to prevent clinical disease, viremia, and virus
shedding in early weaned beef calves possessing maternal immunity that were vaccinated once at 45 days prior
to challenge with virulent BVDV 2.
Results: At 45 days following vaccination, calves that received vaccines B and C had significantly higher BVDV 1
and BVDV 2 serum antibody titers compared with control calves. Serum antibody titers for BVDV 1 and BVDV 2
were not significantly different between control calves and calves that received vaccine D. Following BVDV 2
challenge, a higher proportion of control calves and calves that received vaccine D presented viremia and shed
virus compared with calves that received vaccines B and C. Rectal temperatures and clinical scores were not
significantly different between groups at any time period. Calves that received vaccines B and C had significantly
higher mean body weights at BVDV 2 challenge and at the end of the study compared with control calves.
Conclusions: Moderate to low maternally-derived BVDV antibody levels protected all calves against severe clinical
disease after challenge with virulent BVDV 2. Vaccines B and C induced a greater antibody response to BVDV 1
and BVDV 2, and resulted in reduced viremia and virus shedding in vaccinated calves after challenge indicating a
greater efficacy in preventing virus transmission and reducing negative effects of viremia.
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Bovine viral diarrhea virus (BVDV) is an important
cause of respiratory, enteric, and reproductive disease in
cattle and has been associated with major economic
losses in cattle operations worldwide [1]. Vaccination of
young calves against BVDV reduces the number of acute
infections in the herd and limits spread of virus among* Correspondence: walzpau@auburn.edu
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unless otherwise stated.cattle populations [1,2]; however, effective vaccination of
young calves against BVDV can be challenging due to
the presence of maternally-derived BVDV antibodies at
the time of vaccination [3]. Although maternally-derived
BVDV antibodies can provide protection against acute
BVDV infection and clinical disease, humoral immune
responses to vaccination might be adversely affected [4].
Concentration of maternally-derived BVDV antibodies
and age of calf at the time of vaccination are important
factors in the induction of adequate immune responses
following BVDV immunization [5-7]. Calves with moderateral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ation do not usually respond with an increase in BVDV
antibodies but are protected against clinical disease, have a
slower decay rate of maternal immunity, and develop
anamnestic antibody responses following BVDV challenge
[8-10]. Calves with low maternally-derived BVDV antibody
levels respond to vaccination by increasing BVDV antibody
titers. The priming of naive B and T cells, the induction
of specific cell mediated immune memory responses,
and the induction of anamnestic antibody responses
have been identified as the main source of protection of
young calves vaccinated in the presence of maternally-
derived antibodies and subsequently challenged with
virulent BVDV [11-15].
Early weaned beef calves possess variable levels of
maternally-derived BVDV antibodies at 2–4 months of
age and therefore could benefit from vaccination prior
to stress of weaning and shipment. A single dose of a
multivalent, MLV BVDV vaccine was demonstrated to
be effective in protecting young calves possessing differ-
ent levels of maternal immunity against acute BVDV in-
fection [16]. In addition to prevention of clinical disease,
vaccination should limit the spread of BVDV by redu-
cing virus shedding and horizontal transmission, a de-
sirable outcome of vaccination in herds or units where
populations of highly stressed cattle are commingled.
However, experimental studies comparing different multi-
valent MLV vaccines containing BVDV in their ability to
prevent viremia and viral shedding in young calves pos-
sessing maternally-derived immunity that subsequently
undergo challenge with virulent BVDV are limited. The
objective of this study was to evaluate the ability of
three different commercially available, multivalent MLV
vaccines containing BVDV to prevent clinical disease
and reduce shedding of virus when administered to
early weaned beef calves subsequently challenged with
virulent BVDV 2 at 45 days after vaccination.
Results
Four groups of early weaned beef calves were vaccinated
(B, C, and D) or received phosphate saline (A) at wean-
ing at a median calf age of 72.2 days. The calves were
born from cows that had been previously vaccinated at
least once during the last 2 years with a MLV vaccine.
The vaccine used in the cows during the previous 2 years
was the same vaccine used in experimental calves from
group D. Forty five days after weaning calves were chal-
lenged with BVDV 2 1373. Evaluation of clinical responses
to challenge and sample collection was performed from
day 0 (challenge day) until day 28.
Serum virus neutralization titers
Thirty days prior to vaccination (day −75) and at a median
calf age of 44 days, the mean levels of maternally-derivedBVDV 1 NADL and BVDV 2 125c serum antibodies were
similar between groups (Table 1). At vaccination (day −45),
a significant effect of time (day) was detected (P = 0.0001)
as decay of maternally-derived antibodies for BVDV 1
NADL and BVDV 2 125c occurred in all groups; however,
mean levels of BVDV 1 and BVDV 2 antibodies were not
significantly different (P > 0.05) between groups. Forty-five
days after vaccination, which corresponded to the time of
BVDV 2 challenge (day 0), a significant effect of group
and time (day) was detected (P = 0.0001 and P = 0.0001,
respectively). Groups B and C calves had mean levels of
serum BVDV 1 NADL antibodies significantly greater
than controls (P = 0.0033 and P = 0.0002, respectively).
Additionally, on day 0, mean levels of BVDV 1 NADL
antibodies were similar between group D and the control
group (P = 0.2641). With respect to BVDV 2 125c, group
C calves had mean levels of antibodies significantly greater
than the control group (P = 0.0368). Twenty eight days
following challenge, a significant effect of time (day) was
detected (p = 0.0001) with respect to the levels of BVDV 2
125c. The mean BVDV 2 125c serum antibody levels
increased similarly in all groups (P > 0.05); in contrast,
time (day) and group effects were significant (P = 0.0001
and P = 0.0001, respectively) for BVDV 1 NADL mean
antibody levels as these were higher in group B and C
calves compared to the control group (P < 0.00001).
When antibodies to the challenge strain BVDV 2 1373
were examined at day 0, a significant effect of group
and time (day) was detected (P = 0.0001 and P = 0.0001).
Calves from groups B and C had greater levels of anti-
bodies compared with control calves (P = 0.05 and P =
0.025, respectively). At day 28 after challenge, a significant
(P = 0.0001) effect of time (day) was detected as all groups
had increased and similar levels of antibodies to the
challenge BVDV strain (P > 0.05).
Among vaccinated groups, seroconversion, as defined
as a 4-fold or greater rise in antibody titers to BVDV 1
NADL after vaccination (at day 0) was observed in 16.6%
of the calves from group B, 50% of the calves from group
C, and 9% of the calves from group D. Similarly, serocon-
version to BVDV 2 125c after vaccination was observed in
16.6% of the calves from group B, 8.3% of the calves from
group C, and 9% of the calves from group D. None of the
calves in group A (control) seroconverted to BVDV 1
NADL or BVDV 2 125c. The proportion of calves that
seroconverted to BVDV 2 125c after vaccination was
not significantly different between groups (P > 0.05); how-
ever, a higher proportion of calves from group C (50%)
seroconverted to BVDV 1 NADL with a fourfold increase
in antibody titers.
Virus isolation
Virus positive samples in serum and WBC samples were
detected more frequently and for a longer time in the
Table 1 Geometric mean (95% CI) of virus neutralizing serum antibody titers to BVDV 1, BVDV 2, and BVDV 2 1373
from vaccinated (B, C, and D) and unvaccinated (A) calves at each time period
Day of Study
Virus Group −75 −45 0 28
BVDV 1 NADL A 157.58 (31.12 – 831.74) 60.12 (14.52 – 250.73) 15.03 (5.93 – 38.05) 35.75 (17.38 – 74.02)
B 135.29NS (28.64 – 639.14) 67.64NS (17.50 – 259.57) 107.63* (62.68 – 183.54) 861.07* (377.41 - 1951)
C 222.86NS (67.64 – 765.36) 101.12NS (30.27 – 337.79) 202.25* (110.66 – 369.64) 680.28* (225.97 - 2048)
D 194.01NS (45.56 – 903.88) 95.67NS (22.47 – 407.31) 36.25NS (12.04 – 108.38) 57.70NS (12.99 – 213.78)
BVDV 2 125c A 107.63 (23.10 - 498) 47.83 (13.08 – 173.64) 14.22 (4.08 – 49.18) 608.87 (292.03 – 1260.69)
B 101.12NS (23.26 – 439.58) 60.12NS (15.67 – 232.32) 42.52NS (22.47 – 80.44) 809NS (455.08 – 1438.15)
C 128NS (38.85 – 418.76) 85.03NS (26.53 – 272.47) 60.12* (26.35 – 138.14) 1820.34NS (955.42 – 3468.26)
D 128NS (40.78 – 398.93) 90.50NS (31.34 – 259.57) 29.85NS (15.24 – 58.89) 286.02NS (149.08 – 1541.37)
BVDV 2 1373 A _ _ 16.91 (5.02 – 56.44) 861.07 (424.61 – 1734.13)
B _ _ 76.10* (47.50 – 121.09) 643.59NS (352.13 – 1176.26)
C _ _ 93.05* (49.18 – 176.06) 1530.72NS (617.37 – 3795.30)
D _ _ 56.10NS (28.44 – 11.43) 544.95NS (245.57 – 1200.98)
NS, *Means within BVDV strain and Day of Study are not significantly different (NS) from the control group A or are significantly different (*) based on Dunnett’s
test at P = 0.05.
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The total proportion of calves that tested positive to BVDV
2 in serum and WBC samples after challenge (days 0 to 28)
was higher in the control group (90%) and group D (54.5%)
compared with groups B (16%) and C (25%) (Table 2).
A significant effect of group and time (day) was de-
tected on days 6, 8, 10, and 14 after challenge with
BVDV 2 1373 (P = 0.0001 and P = 0.0001, respectively).
On day 6 post-challenge, the control group had a higher
proportion of calves with positive BVDV samples (58.3%)Figure 1 Total proportion of calves with a positive virus isolation resu
with BVDV 2 1373. The proportion of vaccinated (B, C and D) and contro
time point (day) after challenge with BVDV 2 1373 was higher and more fr
The star *sign refers to statistical significance (P < 0.05).compared with groups B (8.3%) and C (8.3%) (P < 0.05)
but not with group D (36.3%). Additionally, at days 8, 10,
and 14 post-challenge, a higher proportion of calves in the
control group had BVDV positive samples compared with
calves in groups B, C, and D. The proportion of viremic
calves (calves with positive serum or WBC samples) that
shed virus after challenge (calves whose nasal swab sam-
ples tested positive to BVDV by virus isolation) was higher
in the control group (72.7%) compared with groups B (0)
and C (0) and D (33.3%) (P < 0.05).lt in WBC and serum samples at each time point after challenge
l (A) calves with positive virus isolation WBC or serum samples at each
equent in the control group (A) compared with groups B and C and D.
Table 2 Total number and proportion of calves (%) that
became viremic and shed virus in nasal secretions after
challenge (days 0 to 28) with BVDV 2 1373 in each group
Group Number of viremic¥
calves (%)
Number of viremic calves
that shed virus (%)
A 11 (90)* 8 (72.7)*
B 2 (16.6) 0
C 3 (25) 0
D 6 (54.5)* 2 (33.3)
¥, viremic calves = calves with a BVDV positive sample in WBC or serum.
A higher proportion of control (A) and group D calves became viremic and
shed virus after challenge compared with calves from groups B and C. The star
*sign refers to statistical significance (P < 0.05).
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There were no detectable adverse vaccine reactions in
any of the calves. One calf in group D was euthanized
on the day prior to challenge with BVDV 2 1373 due to
rectal prolapse. Vaccinated and control calves demon-
strated clinical protection against challenge with virulent
BVDV 2 1373 as only one calf in the control group de-
veloped mild diarrhea and anorexia on day 14 post-
challenge. The proportion of calves with clinical scores
of ≥ 2 for respiratory, diarrhea, and depression param-
eters was similar between groups (P > 0.05). A mild in-
crease in body temperature, nasal secretion, and loose
feces was observed in all calves after challenge inde-
pendent of group designation. A significant effect of time
(day) on rectal temperatures was observed (P < 0.00001).
On day 8, the mean rectal temperatures of all groups were
increased compared with other days post-challenge.
The average body weight at weaning (day −45) was not
significantly different between groups (A = 206.56 +/− 3.53,
B = 207.25 +/− 8.33, C = 214.08 +/− 9.25, D = 188.41 +/−
10.08); however, a significant effect of group and time (day)Figure 2 Mean white blood cell count (+/−SEM) after challenge with BV
calves after challenge. In all calves mean WBC decreased until day 6 after chal
WBC compared with the control group (P = 0.007).was detected at day 0 and at the end of the study (P =
0.0001 and P = 0.0001, respectively). Calves from group B
and C had significantly higher mean body weights at both
time points compared with control calves (B = 257.5 +/−
13.14, C = 257.5 +/− 11.87 vs. A = 242.5 +/− 11.08 and B =
345 +/− 15.72, C = 333.75 +/− 12.17 vs. A = 267.91 +/−
12.63, respectively). At the same times (day 0 and end of
the trial), the mean body weights of calves from group D
were not significantly different compared with control
calves (240 +/− 15.25 vs. 242.5 +/− 11.08 and 300.90 +/−
14.7 vs. 267.91 +/− 12.63, respectively) (P = 0.568 and P =
0.262, respectively).
Hematology
A significant effect of time (day) but not group was de-
tected in the mean WBC counts, as mean WBC decreased
in all groups from day 0 (challenge) until day 6 post-
challenge (P = 0.0001); however, significant differences
were not observed between groups (P > 0.05). On day 8
post-challenge, a significant effect of group and time (day)
was detected. The mean WBC count from Group D calves
was significantly higher compared with control calves (P =
0.007). At the same time, the mean WBC from calves in
groups B and C were not significantly different compared
to control calves (Figure 2). Effects of group and time
(day) were not detected in platelet counts at any time
point after challenge with BVDV 1373 (Figure 3).
Discussion
High levels of BVDV-specific antibodies from colostrum
or vaccination effectively protect calves against severe
clinical disease induced by challenge with virulent BVDV
[3,9]; however, prevention of viremia and virus shedding
are variable in cattle vaccinated with MLV vaccines and
subsequently challenged with virulent BVDV [17-19]. InDV 2 1373. Mean WBC between vaccinated (B, C, and D) and control (A)
lenge. At day 8 after challenge calves from group D had higher mean
Figure 3 Mean platelet count (+/−SEM) after challenge with BVDV 2 1373. Mean platelet count after challenge with BVDV 2 1373 was not
significantly different between vaccinated (B, C, and D) and control (A) calves.
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ical scores and rectal temperatures, and mortality was not
observed after challenge with virulent BVDV 2 1373. This
could be associated with protection offered by maternally-
derived BVDV antibodies in vaccinated and unvaccinated
calves as has been previously reported [11], or could have
resulted from lower virulence of the challenge virus than
in previous reports [20]. Pestiviruses constantly undergo
genetic change due to the poor proof-reading capability of
the RNA-dependent RNA polymerase, resulting in vari-
ability of phenotypic characteristics such as host-cell trop-
ism and virulence [21]. Repeated passage in cell culture
was previously reported to result in attenuation of a BVDV
isolate, and may have occurred with the BVDV 1373 used
in this study [22].
Interestingly, only calves from group D had an in-
creased white blood cell count compared with control
calves at day 8 post-challenge. Prevention of leukopenia
is one of several parameters used to evaluate response to
vaccination after challenge with BVDV [9,11], and in this
case the lack of a decrease in WBC counts observed in
group D could have been related to the effects of vaccin-
ation or to the presence of high levels of specific mater-
nal antibodies. Despite their ability to reduce clinical
disease, maternally-derived BVDV antibodies were not
as effective in preventing viremia and viral shedding in
calves from the control group as 11/12 (90%) of the
calves became viremic and of those 8/11 (72.2%) shed
virus after challenge. For this study, we chose VI as our
testing method in order to document clinically relevant
shedding of live virus [23]. Prior to challenge, the geo-
metric mean of serum BVDV 2 1373 antibody titers of
control calves was significantly lower compared with
titers from groups B and C (16.91 vs. 76.10 and 93.05,
respectively). Low serum antibody titers prior to chal-
lenge with BVDV have been associated with an increased
risk of viremia and clinical disease as demonstrated inprevious studies [3,4]. Other reports have indicated that
calves with serum maternally-derived BVDV antibody
titers < 64 before challenge with virulent BVDV have a
higher risk of developing clinical disease and systemic
spread of the virus compared to calves with greater
antibody titers [3,8].
Antibody response to vaccination with MLV BVDV
vaccines of young calves in the presence of maternally-
derived BVDV antibodies has produced variable results.
Previous studies have demonstrated that 40 to 90-day-old
calves with maternally-derived antibody titers ≤ 32 against
BVDV 1 and BVDV 2 prior to vaccination seroconvert
after vaccination [5-7,10]; additionally, these calves can de-
velop an anamnestic response when a second dose of vac-
cine is administered [5,10]. In contrast, similar studies
have demonstrated that 3 to 56-day-old calves with BVDV
1 and BVDV 2 maternally-derived antibody titers ≥ 32
prior to vaccination usually do not seroconvert to vaccin-
ation and clinical protection against challenge with BVDV
is variable [4,9,13]. In our study, a small proportion of
calves vaccinated at weaning, at a median age of 72.2 days,
seroconverted to BVDV 2 after vaccination. In contrast,
50% of calves from group C seroconverted to BVDV 1
suggesting a greater ability of the vaccine C to overcome
maternal interference to BVDV 1. The higher levels of
antibodies to BVDV 1 NADL and BVDV 2 1373 before
challenge, the lower proportion of viremia, and the ab-
sence of viral shedding after challenge observed in calves
from groups B and C suggests that vaccination with B and
C may have primed B cell responses to increase specific
antibody production or may have delayed the normal
decay of maternal BVDV antibodies [6-8,10]. Additionally,
the higher levels of antibodies at challenge could have re-
duced viremia and prevented viral shedding in calves from
the same groups. The reduction of viremia and viral shed-
ding is a highly desirable outcome of vaccination since this
could prevent BVDV transmission in operations such as
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from multiple origins are commingled.
The higher proportion of calves with viremia and virus
shedding observed in group D could have been a conse-
quence of the presence of more specific maternal anti-
bodies induced by previous vaccination of the dams with
vaccine D. The presence of more specific BVDV anti-
bodies induced by vaccine D on colostra from the dams
could have exerted a more efficient blockage of humoral
cell responses of calves vaccinated with D. Similar re-
sults were detected in a recent study in which lower
antibody levels to BVDV 1a, BVDV 1b, and BVDV 2 and
a higher proportion of viremia after BVDV 2 challenge
were observed in calves 42 days after vaccination with D
[19]. Protection against viremia and virus shedding after
experimental challenge with BVDV of calves vaccinated
with MLV BVDV vaccines has been commonly associ-
ated with activation of T cell mediated immune re-
sponses independent of the induction of an adequate
antibody response [11,13,14]. A previous study reported
the depletion of CD4+ lymphocytes in calves acutely in-
fected with BVDV could prolong the duration of viral
shedding [24]. Additionally, in another study, 80% of
calves vaccinated at 3 days of age with a MLV BVDV vac-
cine and challenged 7-9 months later with virulent BVDV
2 became viremic after challenge; however, calves were
protected against severe clinical disease in the absence of
antibody responses at initial vaccination [17]. This indi-
cates that induction of specific T cell memory responses
after early vaccination may not always prevent viremia and
virus shedding in young calves after challenge with BVDV.
In the current study we did not evaluate BVDV-specific T
cell responses to vaccination and challenge; however, it is
possible that a stronger activation of T cell memory re-
sponses in calves vaccinated with D that became viremic
could have reduced the duration of viremia to only 2 days;
additionally, T cell memory responses in groups B and C
could have been associated with the reduced proportion of
calves with viremia and nasal shedding.
Previous reports have demonstrated that acute BVDV
infection in young calves can result in decreased weight
gains and decreased performance [9,11]. In the current
study, control calves had lower mean body weights at
day 0 and at the end of the study compared with calves
from groups B and C. Mean body weights of control and
group D calves were similar during the study. It is pos-
sible that vaccines B and C had a positive effect on
weight gain after vaccination as previously reported [25].
Additionally, the higher frequency of viremia in control
and group D calves could have had a negative effect on
performance and weight gain. Another study demon-
strated that young calves vaccinated with a MLV BVDV
vaccine and subsequently challenged with virulent BVDV
have higher mean body weights and average daily gainscompared with non-vaccinated calves [9]. The higher
mean body weights observed in calves from groups B
and C at the end of the study suggest that higher levels
of BVDV antibodies before challenge and prevention of
viremia could have a positive effect on performance,
although this observation would need further research
using larger numbers of experimental subjects. Preven-
tion of weight loss could be a highly desirable outcome
of vaccination programs for early weaned beef calves.Conclusions
Vaccination of young calves possessing maternally-derived
immunity with multivalent MLV vaccines was demon-
strated to be beneficial in reducing viremia and virus
shedding following BVDV challenge at 45 days after
vaccination. Moderate to low levels of maternally-derived
BVDV antibodies protected early weaned beef calves
against severe clinical disease induced by challenge with
virulent BVDV 2. Decay of maternally-derived BVDV anti-
bodies was observed in all groups and just a small propor-
tion of calves seroconverted to BVDV 2 after vaccination;
however, the ability of MLV BVDV vaccines to prime B
cell responses, induce antibody production, or delay the
decay of maternal immunity could result in reduced num-
bers of viremic calves and prevent virus shedding as was
observed in calves from groups B and C in the present
study. Reduction of viremia and BVDV shedding could
result in decreased BVDV transmission and disease by
increasing calf-herd immunity and reducing environmen-
tal load of free virus as has been suggested by a previ-
ous study [26]. Additionally, MLV BVDV vaccines that
reduce viremia after BVDV challenge could have a posi-
tive effect on calf performance and would be of most
benefit when establishing health programs for early weaned
beef calves.Methods
Animals
Forty-eight crossbred steer calves born and raised at
the Upper Coastal Plain Agricultural Research Center,
Winfield, AL were utilized in this study. Calves were
born in September-October 2012 to cows that had re-
ceived at least one dose of a modified-live BVDV vaccine
Da prior to breeding during the 2 years previous to the
start of the study. At birth, calves were identified by an ear
tattoo and ear tag. All calves remained with their dams
and consumption of colostrum occurred under natural
conditions in the pasture. A blood sample for detection of
neutralizing antibodies against BVDV 1 and BVDV 2 was
collected from all calves at day −75 of the study at a
median calf age of 44 days to determine the initial
maternally-derived BVDV antibody levels.
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All calves were early weaned on study day −45, which
corresponded to calf ages between 62–92 days (2–3
months) with a median age of 72.2 days. To prepare for
early weaning, creep feeding was offered for 3 weeks prior
to weaning in order to train calves to the weaning diet.
The weaning diet was an energy dense (65-75% of total di-
gestible nutrients), relatively high protein (14-17%), and
highly palatable ration to meet all nutritional requirements
of young growing calves. Calves were stratified by initial
maternally-derived BVDV 2 serum antibody titers and
assigned by the use of a random number generator b to 1
of 4 different vaccination groups. The stratification by ini-
tial levels of BVDV 2 antibodies ensured that each group
received similar numbers of calves with different levels of
maternally-derived BVDV 2 antibody levels. All calves
underwent abrupt weaning on day −45 of the study and
were vaccinated according to their assigned treatment
group A (n = 12), B (n = 12), C (n = 12), or D (n = 12). Fol-
lowing vaccination, calves were separated in isolated pas-
tures to prevent transmission of vaccine strains between
groups. During this time, daily observation of the calves
was performed to evaluate for adverse vaccine reactions.
Forty-four days after weaning, calves were transported 192
miles to the North Auburn BVDV Unit located in Auburn,
AL. Upon arrival to the North Auburn BVDV Unit, calves
were rested and given access to fresh water, hay, and sup-
plement. On the next day (day 0), all calves were chal-
lenged with virulent BVDV 2 1373 and placed in the same
pasture for the remainder of the study. Clinical evaluation
and sampling of calves was performed until day 28 after
challenge. All calf protocols were reviewed and approved
by the Institutional Animal Care and Use Committee of
Auburn University (PRN # 2012–2157).
Vaccines
All vaccines used were commercially available, USDA-
licensed stock material and were administered to calves
at weaning (day −45). Group A was the control group and
received 2 mL of 0.9% phosphate buffered saline subcuta-
neously once. Group B received 2 mL of vaccine Bc sub-
cutaneously once, group C received 2 mL of vaccine Cd
subcutaneously once, and group D received 2 mL of
vaccine Da subcutaneously once. All vaccines were modified-
live and multivalent containing modified-live types 1
and 2 of BVDV, parainfluenza virus 3, bovine herpesvirus
1, and bovine respiratory syncytial virus. All calves in this
study were under 6 months of age and vaccination with
vaccines B, C, and D was considered off-label.
BVDV challenge
Forty-five days after vaccination (day 0), all calves were
experimentally inoculated with the noncytopathic (NCP)
BVDV 2 strain 1373. The NCP BVDV 2 strain 1373 hasbeen previously used in experimental BVDV inoculation
of calves and shown to induce severe clinical disease,
leukopenia, and thrombocytopenia [27]. The BVDV 2
strain 1373 was propagated in Madin-Darby bovine kid-
ney (MDBK) cells in minimum essential medium j (MEM),
supplemented with 10% equine serum, L-glutamine, peni-
cillin G (100 units/ml), and streptomycin (100 μg/ml).
Virus was harvested from cells by a single freeze-thaw
method, aliquoted, and stored (−80°C) until needed. Ali-
quots were enumerated using the method of Reed and
Muench [28], prior to inoculation of calves. All calves were
inoculated by intranasal aerosol administration of 1 × 106
TCID50 of the BVDV 2 strain 1373.
Sample and data collection
Daily clinical observations were performed by the same
person, who was blinded to study group allocation, on
days 0, 3, 6, 8, 10, 14, 21, and 28. Additionally, individual
rectal temperatures, serum, whole blood, and deep nasal
swab samples were collected on those same days. Whole
blood samples were subjected to hematologic analysis on
day 0 prior to challenge and on days 6, 8, 10, and 28
after challenge for individual white blood cell and plate-
let counts.
During sampling days, each calf was scored prior to
handling for signs of abnormal respiration, diarrhea, and
depression using a scale of 0 to 3, with the absence of a
clinical sign scored as 0 and the most severe clinical sign
scored as 3 [17]. Briefly, an abnormal respiratory score
was given if an animal presented with a cough, labored
breathing, nasal, or ocular discharge. Nasal and ocular
discharges were judged as being serous, mucous, or muco-
purulent. Diarrhea scores were judged as being normal
feces, pasty feces, runny feces, or severe diarrhea with or
without blood. Depression scores ranged from no depres-
sion, mild depression, moderate depression, or severe
depression. In addition to visual examination, individual body
weights were obtained on day −45 (vaccination/weaning
day), day 0 (challenge day), and days 14, and 28 after
challenge using a portable livestock electric scale f that
was validated prior to and after each weighing.
Virus Isolation (VI)
Whole blood, serum, and deep nasal swab samples col-
lected on days 0, 3, 6, 8, 10, 14, 21, and 28 after challenge
were used for BVDV VI using the immunoperoxidase
monolayer assay with techniques previously described
[29]. Briefly, the isolated samples were suspended in
24-well plates and subsequently seeded in 50 μL culture
medium. The cell suspension was subjected to co-
cultivation on 25 cm3 flasks containing monolayers of
MDBK cells and was incubated for 24 hours at 38.5°C
and 5% CO2. Following cultivation, 50 μl of the cell cul-
ture supernatant was inoculated in triplicate into wells
Chamorro et al. BMC Veterinary Research  (2015) 11:29 Page 8 of 9on 96-well microtiter plates containing monolayers of
MDBK cells in culture medium. After 96 hours of incu-
bation at 38.5°C and 5% CO2, all samples were frozen
at −80°C and subsequently thawed to detect BVDV
using the immunoperoxidase monolayer assay as previ-
ously described [29].
Virus Neutralization (VN)
The standard virus neutralization microtiter assay was
used to detect antibodies against BVDV in serum of calves
collected on days −75, −45, 0 (prior to challenge), and 28
[28]. The BVDV 1 cytopathic strain NADL and BVDV 2
cytopathic strain 125c were used. For samples collected on
days 0 and 28, the challenge BVDV 2 1373 non-cytopathic
strain was also used. Briefly, following heat inactivation at
56°C for 30 minutes, serial 2-fold dilutions (1:2 to 1:4096)
were made in 50 μL of culture medium. For each dilution,
3 wells of a 96-well plate were inoculated with an equal
volume (50 μL) of culture medium containing 100–500
TCID50 of the test strain. After inoculation, the plate was
incubated at 38.5°C in a humidified atmosphere of 5%
CO2 and room air for 1 hour. Then, 2.5 × 10
3 MDBK cells
in 50 μL of culture medium were added to each well.
Plates were incubated for 72 hours and evaluated visually
for cytopathic effect for the BVDV 1 and 2 cytopathic
strains [29,30] or by staining the plates using the immuno-
peroxidase assay for the BVDV 2 1373 non-cytopathic
strain. The geometric mean of antibody titers was calcu-
lated from the endpoint Log2 titers of the animals in each
group. Seronegativity to BVDV 1 and BVDV 2 was defined
as a serum antibody titer less than 2 which equates to a
Log2 antibody titer of 0.
Statistical analysis
All statistical analyses were performed using the GLIMMIX
procedure in the SAS 9.3 software package g. To detect
changes in Log2 transformed antibody levels, virus isolation,
rectal temperatures, white blood cell counts, platelet
counts, and body weights, a repeated measures generalized
linear mixed model [Response =Group +Time (day) +
Group * Day] was performed using an appropriate distribu-
tion function. The repeated nature of this experiment, viz.
multiple observations on the same experimental unit = ani-
mal over time, implies non-independence of residuals.
Hence, the residual variance was modelled to arrive at a
reasonable residual covariance structure using Akaike’s
Information criterion corrected for small sample sizes
(AICc) to determine the best structure. A first-order auto-
regressive structure with heterogeneous variances (ARH 1)
was most commonly fitted. This structure allows for a sep-
arate residual variance at each time point and a correlation
among time points that diminishes with the lag. Because
clinical scores for respiratory distress and diarrhea were
binary in nature (only scores 1 and 2 were given) the binarydistribution function was used in the abovementioned
procedure; this analysis approach is commonly referred to
as logistic regression. No analysis was performed for clinical
depression score as all scores equalled zero. Dunnett’s test
for multiple comparisons was used to detect differences
between vaccinated groups and the control group; a prob-
ability of P ≤ 0.05 was considered statistically significant for
all tests. The FREQ procedure in the abovementioned
software package h was used to analyze the proportion of
calves with viremia and virus shedding with a χ2 test.
Endnotes
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fTrue-test Inc. Mineral Wells, TX
gSAS Institute Inc., Cary, NC
hPROC FREQ SAS 9.2, SAS Institute Inc., Cary, NC
Abbreviations
BVDV: Bovine viral diarrhea virus; MLV: Modified- live virus; CP: Cytopathic;
NCP: Non-cytopathic; VI: Virus isolation; VN: Virus neutralization.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MFC, PHW, and TP developed the experimental design of this study and
co-wrote the manuscript. EvS performed the statistical analysis of the data
and revised the manuscript. KPR, JG, and SPR collaborated with animal
experiments, sampling, and data collection. PG and YZ performed laboratory
testing. All authors read and approved the final manuscript.
Acknowledgements
The authors would like to thank Mr. George Fincher and Mr. Steven
Ledbetter for animal care assistance.
Funding
Funds for this research project were obtained from the Alabama Agricultural
Experimental Station, Auburn, AL.
Author details
1Department of Clinical Sciences, College of Veterinary Medicine, Auburn
University, Auburn, AL, USA. 2Department of Pathobiology, College of
Veterinary Medicine, Auburn University, Auburn, AL, USA. 3Department of
Animal Sciences, College of Agriculture, Auburn University, Auburn, AL, USA.
4Department of Crop, Soils, and Environmental Sciences, College of
Agriculture and Alabama Agricultural Experiment Station, Auburn University,
Auburn, AL, USA.
Received: 25 October 2014 Accepted: 29 January 2015
References
1. Houe H. Epidemiology of bovine viral diarrhea virus. Vet Clin North Am
Food Anim Pract. 1995;11:521–47.
2. Ridpath JF. Immunology of BVDV vaccines. Biologicals. 2013;41:14–9.
3. Cortese VS, West KH, Hassard LE, Carman S, Ellis JA. Clinical and immunologic
responses of vaccinated and unvaccinated calves to infection with a virulent
type-II isolate of bovine viral diarrhea virus. J Am Vet Med Assoc.
1998;213:1312–9.
Chamorro et al. BMC Veterinary Research  (2015) 11:29 Page 9 of 94. Ellis J, West K, Cortese V, Konoby C, Weigel D. Effect of maternal antibodies
on induction and persistence of vaccine-induced immune responses against
bovine viral diarrhea virus type II in young calves. J Am Vet Med Assoc.
2001;219:351–6.
5. Menanteau-Horta AM, Ames TR, Johnson DW, Meiske JC. Effect of maternal
antibody upon vaccination with infectious bovine rhinotracheitis and
bovine virus diarrhea vaccines. Can J Comp Med. 1985;49:10–4.
6. Munoz-Zanzi CA, Thurmond MC, Johnson WO, Hietala SK. Predicted ages of
dairy calves when colostrum-derived bovine viral diarrhea virus antibodies
would no longer offer protection against disease or interfere with vaccination.
J Am Vet Med Assoc. 2002;221:678–85.
7. Fulton RW, Briggs RE, Payton ME, Confer AW, Saliki JT, Ridpath JF, et al.
Maternally derived humoral immunity to bovine viral diarrhea virus (BVDV)
1a, BVDV1b, BVDV2, bovine herpesvirus-1, parainfluenza-3 virus bovine
respiratory syncytial virus, Mannheimia haemolytica and Pasteurella multocida
in beef calves, antibody decline by half-life studies and effect on response to
vaccination. Vaccine. 2004;22:643–9.
8. Howard CJ, Clarke MC, Brownlie J. Protection against respiratory infection
with bovine virus diarrhoea virus by passively acquired antibody. Vet
Microbiol. 1989;19:195–203.
9. Platt R, Widel PW, Kesl LD, Roth JA. Comparison of humoral and cellular
immune responses to a pentavalent modified live virus vaccine in three age
groups of calves with maternal antibodies, before and after BVDV type 2
challenge. Vaccine. 2009;27:4508–19.
10. Woolums AR, Berghaus RD, Berghaus LJ, Ellis RW, Pence ME, Saliki JT, et al.
Effect of calf age and administration route of initial multivalent modified-live
virus vaccine on humoral and cell-mediated immune responses following
subsequent administration of a booster vaccination at weaning in beef
calves. Am J Vet Res. 2013;74:343–54.
11. Ridpath JF, Neill JD, Endsley J, Roth JA. Effect of passive immunity on the
development of a protective immune response against bovine viral diarrhea
virus in calves. Am J Vet Res. 2003;64:65–9.
12. Endsley JJ, Roth JA, Ridpath J, Neill J. Maternal antibody blocks humoral but
not T cell responses to BVDV. Biologicals. 2003;31:123–5.
13. Zimmerman AD, Boots RE, Valli JL, Chase CC. Evaluation of protection
against virulent bovine viral diarrhea virus type 2 in calves that had
maternal antibodies and were vaccinated with a modified-live vaccine.
J Am Vet Med Assoc. 2006;228:1757–61.
14. Endsley JJ, Quade MJ, Terhaar B, Roth JA. Bovine viral diarrhea virus type
1- and type 2-specific bovine T lymphocyte-subset responses following
modified-live virus vaccination. Vet Ther. 2002;3:364–72.
15. Endsley JJ, Ridpath JF, Neill JD, Sandbulte MR, Roth JA. Induction of T
lymphocytes specific for bovine viral diarrhea virus in calves with maternal
antibody. Viral Immunol. 2004;17:13–23.
16. Step DL, Krehbiel CR, Burciaga-Robles LO, Holland BP, Fulton RW, Confer
AW, et al. Comparison of single vaccination versus revaccination with a
modified-live virus vaccine containing bovine herpesvirus-1, bovine viral
diarrhea virus (types 1a and 2a), parainfluenza type 3 virus, and bovine
respiratory syncytial virus in the prevention of bovine respiratory disease
in cattle. J Am Vet Med Assoc. 2009;235:580–7.
17. Stevens ET, Brown MS, Burdett WW, Bolton MW, Nordstrom ST, Chase CC.
Efficacy of a non-adjuvanted, modified-live virus vaccine in calves with maternal
antibodies against a virulent bovine viral diarrhea virus type 2a challenge seven
months following vaccination. Bovine Pract. 2011;45:23–31.
18. Palomares RA, Givens MD, Wright JC, Walz PH, Brock KV. Evaluation of the
onset of protection induced by a modified-live virus vaccine in calves
challenge inoculated with type 1b bovine viral diarrhea virus. Am J Vet
Res. 2012;73:567–74.
19. Ridpath JF, Dominowski P, Mannan R, Yancey Jr R, Jackson JA, Taylor L.
Evaluation of three experimental bovine viral diarrhea virus killed vaccines
adjuvanted with combinations of Quil A cholesterol and
dimethyldioctadecylammonium (DDA) bromide. Vet Res Commun.
2010;34:691–702.
20. Stoffregen BL, Bolin SR, Ridpath JF, Pohlenz J. Morphologic lesions in type 2
BVDV infections experimentally induced by strain BVDV2-1373 recovered
from a field case. Vet Microbiol. 2000;77:157–62.
21. Moya A, Elena SF, Bracho A, Miralles R, Barrio E. The evolution of RNA viruses:
A population genetics view. Proc Natl Acad Sci U S A. 2000;97:6967–73.
22. Deregt DL, Jacobs RM, Carman PS, Tessaro SV. Attenuation of a virulent type
2 bovine viral diarrhea virus. Vet Microbiol. 2004;100:151–61.23. Dubey P, Mishra N, Rajukumar K, Behera SP, Kalaiyarasu S, Nema RK, et al.
Development of a RT-PCR ELISA for simultaneous detection of BVDV-1,
BVDV-2 and BDV in ruminants and its evaluation on clinical samples. J Virol
Methods. 2014;213C:50–6.
24. Howard CJ, Clarke MC, Sopp P, Brownlie J. Immunity to bovine virus diarrhoea
virus in calves: the role of different T-cell subpopulations analysed by specific
depletion in vivo with monoclonal antibodies. Vet Immunol Immunopathol.
1992;32:303–14.
25. Tait Jr RG, Downey ED, Mayes MS, Park CA, Ridpath JF, Garrick DJ, et al.
Evaluation of response to bovine viral diarrhea virus type 2 vaccination and
timing of weaning on yearling ultrasound body composition, performance,
and carcass quality traits in Angus calves. J Anim Sci. 2013;91:5466–76.
26. Thurmond MC, Munos-Zansi CA, Hietala SK. Effect of calfhood vaccination
on tranmission of bovine viral diarrhea virus under typical drylot dairy
conditions. J Am Vet Med Assoc. 2001;219:968–75.
27. Brock KV, Widel P, Walz P, Walz HL. Onset of protection from experimental
infection with type 2 bovine viral diarrhea virus following vaccination with a
modified-live vaccine. Vet Ther. 2007;8:88–96.
28. Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints.
Am J Hyg. 1938;27:493–7. 71:5–6822.
29. Walz PH, Givens MD, Cochran A, Navarre CB. Effect of dexamethasone
administration on bulls with a localized testicular infection with bovine
viral diarrhea virus. Can J Vet Res. 2008;72:56–62.
30. Larska M, Polak MP, Liu L, Alenius S, Uttenthal A. Comparison of the
performance of five different immunoassays to detect specific antibodies
against emerging atypical bovine pestivirus. J Virol Methods. 2013;187:103–9.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
